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Abstract
A drug therapy can alter the pharmacokinetic profiles and biodistribution patterns of
radiopharmaceuticals. Glucocorticoids are pharmaceutical drugs for anti-inflammatory by
preventing phospholipid release and decreasing eosinophil action. To achieve an optimum
diagnostic outcome, this research was focused on pharmacokinetics interaction and biodistribution
pattern between two kinds of Glucocorticoids drugs i.e. dexamethasone and prednisone with 99mTc-
MDP using animal model Mus musculus stock Swiss. 99mTc-MDP has been developed as
radiopharmaceutical for bone imaging in nuclear medicine. Mice were divided into three groups,
which were treated with dexamethasone by oral administration for 5 days continously, treatment
with prednisone by oral administration for 3 days continously and without treatment (control).
Pharmacokinetics interaction was conducted by injecting 200L 99mTc-MDP intravenously
administrated using a dose 1 Ci/L. Biodistribution pattern was conducted by injecting 200 L
99mTc-MDP intravenously administrated using a dose 1 Ci/L. After 3 hours after intravenous
injection of 99mTc-MDP each of these groups of animals were killed with chloroform and then
dissected. Radioactivity of blood samples and selected organs were weighed and counted by using
single channel analyzer. The results of pharmacokinetics study showed that the elimination half-life
of animal model that given with dexamethasone and prednisone are 4.61 h and 4.63 h more faster
than control animals (20.67 h). The results of biodistribution study showed that uptake of 99mTc-
MDP in bone using animal models decreased which were given dexamethasone and prednisone
compared to normal animals, which following results 3.53 ± 0.49%, 3.47 ± 0.5% and 11.54 ±
4.36% (control).
Key words: 99mTc-MDP Radiopharmaceuticals, Pharmacokinetics Interaction,
Glucocorticoids, biodistribution pattern.
Introduction
99mTc-MDP radiopharmaceuticals have been clinically approved and widely used for bone imaging in
nuclear medicine (Schwochau, 2000). This complexes are preferable because there are more stable in
vivo than P-O-P bond of phosphates. P-O-P bond can be easily broken down by phosphatase enzymes,
but the P-C-P bond in diphosphonate of 99mTc-MDP is not affected (Khalil, 2011). This complexes were
used for metastatic bone cancer because their high sensitivity can detect metastases before
occurrence of anatomical changes (Ogawa & Ishizaki, 2015) (Goyal & Antonarakis, 2012).
Radiopharmaceuticals are used for two purposes. The first is their use as a traced compound
administered to a patient for observing physiological alterations or abnormal distribution throughout of
the body and the second is their use as a tracer for biochemical or physiological studies (Santos-
Oliveira, 2008). The pharmacokinetics or biodistribution of radiopharmaceutical may alter by a variety
of drugs, disease states and surgical procedurs (Santos-Oliveira, 2008), which a significant clinical
impact on safety, scan interpretation, and diagnostic imaging accuracy (Factors, 2010).
In a previous study, it was known that aluminium containing drugs , nifedipine, etidronate,
pamidronate and vitamin D could reduce bone uptake of 99mTc-MDP and 99mTc-HDP (Factors, 2010).
Glucocorticoids have become one of the most widely used and effective treatments for various
inflammatory for palliative treatment. Administration of Glucocorticoids especially for long term
systemic by oral or parenteral can induce bone loss, osteoporosis and fractures, adrenal suppression,
hyperglycemia, diabetes, cardiovascular disease, and immunosuppression (Liu et al., 2013). This
research is focused on studying the Glucocorticoids drug interactions with 99mTc-MDP
radiopharmaceutical using mice stock swiss through observation the changes in pharmacokinetics
profiles and biodistribution pattern.
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Materials and Methods
The materials to carry out in this research were MDP (Sigma Aldrich), SnCl2.2H2O (Sigma Aldrich),
NaOH (E. Merck), HCl (E. Merck), aquadest (IPHA laboratories), radionuclide Technetium-99m from
generator 99Mo/99mTc (POLATOM), Whatman 3MM paper (Whatmann) and pH Universal Indicator (E.
Merck). The equipments used were single channel analyzer NaI(TL) detector (Ortec), TLC scanner
(Bioscan 2000), Deluxe Isotope Calibration (Victoreen), vial 10 mL, micro pipette (eppendorf),
analytical scale (Mettler Toledo), oven (Memmert), disposable syringe (Terumo) and other glass tools.
Animals
This research used 24 male mice (Mus musculus) stock Swiss, each weighing 36-44 gram. This
research was approved by the ethics Committee for Care and Use of Laboratory Animals (KEPPHP
BATAN) with ethical approval number 003/KEPPHP-BATAN/IV/2015 and was performed according to
guidelines on animal experimentation.
Statistical Analysis
The data were calculated to an unpaired, two-tailed distribution student t-test by statplus program,
with 95% of confidence level.
Radiolabeling of 99mTc-MDP and determination of radiochemical purity (Zolle, 2007)
The freeze-dried MDP kit was reconstituted using 1 mL of freshly eluted 99mTcO4 solution containing 1-
3 mCi of radioactivity. The solution was stirred for 1 minute and incubated 30 minutes at the room
temperature. The radiochemical purity was determined by ascending paper chromatography method
using acetone and saline as mobile phase and whatmann 3MM as stationary phase. Paper
chromatogram was dried in oven at 80°C for 5 minutes and then every 1 cm piece of paper is
measured by the single-channel gamma counter detector NaI (Tl).
Pharmacokinetic Study
The pharmacokinetic study were performed by injecting 0.1 mL of 99mTc-MDP intravenously with a
dose 1 µCi/µL in animals group I, II and III, which each group consists of three animals. The blood
samples were collected from animal tail at 0,833; 1; 2; 3; 4; 5; 6; 24; 25; 26 hours after injection of
99mTc-MDP. The blood samples were weighed and then the radioactivity was measured using a single
channel analyzer with Na(I)TL detector. Samples were calculated and analyzed to get percentage of
injection dose per gram samples (%ID/g) and the half life (t1/2) of distribution and elimination of
99mTc-MDP were calculated using Multifit software (version 8/2000, developed by Dr. J.H.Proost,
University Center for Pharmacy, Groningen, The Netherlands).
Biodistribution study
Normal animal group I and animal models group II and III were injected with 0.1 mL of 99mTc-MDP
with a dose of 1 µCi/µL intravenously through the tail. Then, 3 hours after intravenous injection, the
animals were killed with chloroform and the vital organs were taken such as muscle, bone, blood,
intestine, stomach, liver, spleen, kidneys, heart and lungs. Samples were collected, weighed, and the
radioactivity of each samples were counted using single channel analyzer with Na(I)TL detector. The
accumulation of each organ samples were calculated as percentage of injection dose per gram organ.
Results and Discussion
Radiochemical purity is one of the requirements of radiopharmaceutical quality testing in addition to
clarity, vacuum and pH. Radiochemical purity was determined by ascending paper chromatography
system. As shown in Figure 1, acetone as a mobile phase was used to separate pertechnetate and
saline (NaCL 0.9%) was used to separate the reduced technetium, then the percentage of
radiochemical purity was calculated based on a calculation formula of 100% - %(TcO4- + TcO2). The
results of this test showed that 99mTc-MDP radiopharmaceuticals had 97.92 ± 1.93% radiochemical
purity (n=5) with impurity of TcO2 was 1.88 ± 1.92% and TcO4- was 0.71 ± 1.18%. The 99mTc-MDP
radiopharmaceuticals have been fulfilled the requirement of United State of Pharmacopoeia, which the
percentage of radiochemical purity is greater than 95%. The solution of MDP dissolved easily in saline,
giving a clear and colorless solution, vacuum and pH between 5.8 – 6.0.
The pharmacokinetic profile was conducted to determine the rate of distribution and elimination of
99mTc-MDP radiopharmaceutical in the body through the determination of its biological half life. As
shown in Figure 2, percentage of injection dose of 99mTc-MDP in animal models treatment
dexamethasone and prednisone for several days showed an increase compared to the control, results
at 13.28 ± 2.79 % ID/g and 13.56 ± 3.85% ID/g, respectively than control at 2.08 ± 0.36% ID/g.
Treatment of dexamethasone and prednisone was similar to pharmacokinetic profile (Fig. 2).
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Figure 1. The chromatogram of 99mTc-MDP using (A) acetone as mobile phase and (B) saline as
mobile phase
About 12.34 and 12.06% of the injected dose remains in the blood at 1 hour post-injection and 0.19
and 0.18% at 24 hours, 99mTc-MDP were treatment with dexamethasone and prednisone. Following
intravenous administration, 99mTc-MDP is cleared from the plasma with a half-time of 3–4 min. About
10% of the injected dosage remains in the blood at 1 hour post-injection and less than 1% at 24
hours (Saha, 2010).
Figure 2. Pharmacokinetics profile of 99mTc-MDP using normal mice stock swiss with treatment of
dexamethasone and prednisone and without treatment as control.
Based on calculations by the multifit software (Table 1), it showed that the distribution half-life of
99mTc-MDP with treatment did not differ significantly from control. But the elimination half-life showed
a significant difference where the biological half-life of 99mTc-MDP radiopharmaceutical which
treatment with dexametasone (4.61 h) and prednisone (4.43 h), the half-life more faster than control
(20.67 h).
Table 1. Distribution and elimination half-life of 99mTc-MDP radiopharmaceutical given Glucocorticoids
drug treatment compared to controls without treatment using Multifit software
t1/2 distribution
(hours)
t1/2 elimination
(minutes)
Controls (without treatment) 0.21 20.67
Treatment of Dexamethasone 0.23 4.61
Treatment of Prednisone 0.20 4.43
Biodistribution study was performed 3 hours after intravenous injection of 99mTc-MDP to animal model.
In nuclear medicine, imaging of bone scintigraphy using 99mTc-MDP usually performed 2-5 hours
afterwards for clearance of the administrated radiopharmaceutical from  the intravascular
compartment and from the extracellular nonosseous soft tissues (Zuckier & Martineau, 2015).
99mTc-MDP + 99mTcO2 99mTc-MDP
+ 99mTcO4-
99mTcO299mTcO4-
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The administration of dexamethasone and prednisone for several days has changed the pattern of
biodistribution particularly on the bone. As shown in Figure 3, the highest percentage shown in the
bone, but the bones which given treatment with dexamethasone and prednisone reduced bone uptake
than control, results were 3.53 ± 0.49 % and 3.47 ± 0.5%, respectively which compared to the
control 11.54 ± 4.36% (t test, differ significantly with the 95% confidence level). Dexamethasone and
prednisone, glucocorticoids agent, are common to control and treat several inflammatory diseases and
side effect of this agents especially for long term is bone loss through decrease quality and quantity of
mineral bone density and rate of osteogenesis (Doroudi et al., 2012). A small amount of bone
synthesis depends on decreased calcium availability and decreased glucocorticoid-induced osteoblastic
activity (Longui, 2007). Based on t-test, uptake of non target organs showed there are no significantly
differences between treatments and controls. Non target organs have lower uptake than bone (target
organ), which are below than 2.5% of injected dose per gram.
Figure 3. Biodistribution profile of 99mTc-MDP using normal mice stock swiss with treatment of
dexamethasone and prednisone and without treatment
Conclusions
Administration of dexamethasone and prednisone as glucocorticoid agent can alter pharmacokinetics
profile and biodistribution pattern. Treatment of dexamethasone and prednisone decreases bone
uptake and elimination half-life of 99mTc-MDP radiopharmaceuticals
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